Core Insights - Raphael Pharmaceutical Inc. has filed a provisional patent application for its cannabinoid-based technology platform aimed at treating neutrophil-dominant autoimmune diseases, including rheumatoid arthritis [1][2][4] - The company has reported positive proof-of-concept clinical study results for its lead product candidate, RaphaWell, demonstrating significant improvements in pain and overall well-being for rheumatoid arthritis patients [3][8] Group 1: Patent Application and Collaboration - The provisional patent application covers the use of a highly purified cannabinoid-based technology platform for treating autoimmune diseases, filed jointly with Rambam Health Care Campus [2][4] - Raphael has a collaboration with Rambam under a sponsored research agreement since 2019, providing exclusive access to advanced cannabinoid research led by Dr. Igal Louria-Hayon [5] Group 2: Clinical Study Results - The proof-of-concept clinical study for RaphaWell showed no adverse effects and significant improvements in pain, sleep quality, and overall well-being, with reductions in Disease Activity Score (DAS28) from high to moderate disease activity [3][8] - The study was conducted over eight weeks in the U.S. under Institutional Review Board approval, with positive results evident as early as week four [8] Group 3: Product Development and Market Potential - RaphaWell is designed for targeted, orally accessible delivery to rheumatoid arthritis patients and is free of psychoactive components [10] - The company believes its proprietary cannabinoid formula has the potential to provide a safe and cost-effective treatment option for millions suffering from rheumatoid arthritis and may have broader applications in other chronic inflammatory conditions [6][7]